Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Subcutaneous vs Intravenous Aducanumab in Healthy Volunteers
NCT04924140Phase 1Completed
- Sponsor
- Biogen
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aducanumab in Alzheimer's disease (AD), sponsored by Biogen. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity and Maximum Observed Concentration. Started Jun 2021; status: completed.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04924140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924140.